Elevation Oncology, Inc. Profile
Industry
BiotechnologySector
HealthcareNumber of Employees
29Elevation Oncology's Business Model
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
About Elevation Oncology
Website: https://elevationoncology.com
CEO (Chief Executive Officer): Mr. Joseph J. Ferra Jr.
IPO date: 2021-06-25
Contact
Country: US
Address: 888 Seventh Avenue
City: New York
State: NY
Phone: 716 371 1125
Zip Code: 10106
Other
CIK: 0001783032
ISIN: US28623U1016
CUSIP: 28623U101
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
